

List of all peer-reviewed publications indexed in PubMed up until August 14th 2023 (n=153):

1: Stenman A, Falhammar H, Zedenius J, **Juhlin CC**. Adrenal and periadrenal schwannoma: histological, molecular and clinical characterization of an institutional case series. *Endocrine*. 2023 Aug 3. doi: 10.1007/s12020-023-03463-y. Epub ahead of print. PMID: 37535242.

2: Hysek M, Hellgren SL, Condello V, Xu Y, Larsson C, Zedenius J, **Juhlin CC**. 5hmC Immunohistochemistry: A Predictor of *TERT* Promoter Mutational Status in Follicular Thyroid Carcinoma? *J Histochem Cytochem*. 2023 Aug;71(8):451-458. doi: 10.1369/00221554231190437. Epub 2023 Jul 24. PMID: 37486076.

3: Nilsson JN, Siikanen J, Condello V, Jatta K, Saini R, Hedman C, Ihre Lundgren C, **Juhlin CC**. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. *Eur Thyroid J*. 2023 Jul 28;12(4):e230099. doi: 10.1530/ETJ-23-0099. PMID: 37352166; PMCID: PMC10388652.

4: Nilsson JN, Grybäck P, **Juhlin CC**, Hedman C, Lundgren CI. Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer. *Endocrine*. 2023 Jun 7. doi: 10.1007/s12020-023-03414-7. Epub ahead of print. PMID: 37284971.

5: Mete O, **Juhlin CC**. Progress in Adrenal Cortical Neoplasms: From Predictive

Christofer Juhlin, 791009-5632

Histomorphology to FLCN-Driven Germline Pathogenesis and the Prognostic Performance of Multiparameter Scoring Systems in Pediatric Adrenal Cortical Neoplasms. *Endocr Pathol.* 2023 Jun;34(2):176-178. doi: 10.1007/s12022-023-09776-y. Epub 2023 May 23. PMID: 37219723.

6: Calissendorff J, **Juhlin CC**, Sundin A, Bancos I, Falhammar H. Adrenal cysts: an emerging condition. *Nat Rev Endocrinol.* 2023 Jul;19(7):398-406. doi: 10.1038/s41574-023-00835-2. Epub 2023 Apr 24. PMID: 37095252.

7: Dogra P, Sundin A, **Juhlin CC**, Calissendorff J, Falhammar H, Bancos I. Rare benign adrenal lesions. *Eur J Endocrinol.* 2023 Apr 5;188(4):407-420. doi: 10.1093/ejendo/1vad036. PMID: 36943310.

8: **Juhlin CC**, Bal M. Top 10 Histological Mimics of Neuroendocrine Carcinoma You Should Not Miss in the Head and Neck. *Head Neck Pathol.* 2023 Mar;17(1):66-84. doi: 10.1007/s12105-022-01521-x. Epub 2023 Mar 20. PMID: 36941503; PMCID: PMC10063750.

9: Hysek M, Hellgren LS, Stenman A, Darai-Ramqvist E, Ljung E, Schliemann I, Condello V, Larsson C, Zedenius J, Jatta K, **Juhlin CC**. Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: A highly specific technique for pre-operative identification of high-risk cases. *Diagn Cytopathol.* 2023 Jun;51(6):331-340. doi: 10.1002/dc.25120. Epub 2023 Mar 4. PMID: 36870048.

Christofer Juhlin, 791009-5632

10: Haissaguerre M, Louiset E, **Juhlin CC**, Stenman A, Laurent C, Trouette H, Lefebvre H, Tabarin A. Immunohistochemical characterization of a steroid-secreting oncocytic adrenal carcinoma responsible for paraneoplastic hyperparathyroidism. *Eur J Endocrinol*. 2023 Apr 5;188(4):K11-K16. doi: 10.1093/ejendo/lvad025. PMID: 36869749.

11: **Juhlin CC**. On the Chopping Block: Overview of DICER1 Mutations in Endocrine and Neuroendocrine Neoplasms. *Surg Pathol Clin*. 2023 Mar;16(1):107-118. doi: 10.1016/j.path.2022.09.010. Epub 2022 Dec 12. PMID: 36739158.

12: Lindfors H, Karlsen M, Karlton E, Zedenius J, Larsson C, Ihre Lundgren C, **Juhlin CC**, Shabo I. Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer. *Sci Rep*. 2023 Jan 19;13(1):1070. doi: 10.1038/s41598-023-27684-3. PMID: 36658256; PMCID: PMC9852547.

13: Solhusløkk Höse K, Stenman A, Svahn F, Larsson C, **Juhlin CC**. TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome? *Endocr Pathol*. 2023 Mar;34(1):129-141. doi: 10.1007/s12022-022-09746-w. Epub 2023 Jan 19. PMID: 36656469; PMCID: PMC10011289.

14: **Juhlin CC**, Hysek M, Stenman A, Zedenius J. Papillary Thyroid Carcinoma with Desmoid-Like Fibromatosis: Double Trouble? *Endocr Pathol*. 2022 Dec;33(4):525-527. doi: 10.1007/s12022-022-09735-z. Epub 2022 Oct 15. PMID:

Christofer Juhlin, 791009-5632

36242758; PMCID: PMC9712337.

15: **Juhlin CC**, Mete O. Advances in Adrenal and Extra-adrenal Paraganglioma: Practical Synopsis for Pathologists. *Adv Anat Pathol*. 2023 Jan 1;30(1):47-57. doi: 10.1097/PAP.0000000000000365. Epub 2022 Sep 23. PMID: 36136370.

16: Liu Y, Helgadottir HT, Kharaziha P, Choi J, López-Giráldez F, Mane SM, Höiom V, **Juhlin CC**, Larsson C, Bajalica-Lagercrantz S. Whole-Exome Sequencing of Germline Variants in Non-*BRCA* Families with Hereditary Breast Cancer. *Biomedicines*. 2022 Apr 26;10(5):1004. doi: 10.3390/biomedicines10051004. PMID: 35625741; PMCID: PMC9138793.

17: **Juhlin CC**, Zedenius J, Höög A. Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup. *Cancers (Basel)*. 2022 Apr 28;14(9):2210. doi: 10.3390/cancers14092210. PMID: 35565339; PMCID: PMC9100271.

18: Xing X, Mu N, Yuan X, Wang N, **Juhlin CC**, Strååt K, Larsson C, Neo SY, Xu D. Downregulation and Hypermethylation of *GABPB1* Is Associated with Aggressive Thyroid Cancer Features. *Cancers (Basel)*. 2022 Mar 8;14(6):1385. doi: 10.3390/cancers14061385. PMID: 35326537; PMCID: PMC8946831.

19: Hellgren LS, Stenman A, Paulsson JO, Höög A, Larsson C, Zedenius J, Juhlin CC. Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center. *Endocr Pathol*. 2022 Jun;33(2):231-242. doi: 10.1007/s12022-022-09714-4. Epub 2022 Mar 19. PMID:

Christofer Juhlin, 791009-5632

35305239; PMCID: PMC9135869.

20: Mete O, Erickson LA, **Juhlin CC**, de Krijger RR, Sasano H, Volante M, Papotti MG. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. *Endocr Pathol.* 2022 Mar;33(1):155-196. doi: 10.1007/s12022-022-09710-8. Epub 2022 Mar 14. PMID: 35288842; PMCID: PMC8920443.

21: Baloch ZW, Asa SL, Barletta JA, Ghossein RA, **Juhlin CC**, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O. Overview of the 2022 WHO Classification of Thyroid Neoplasms. *Endocr Pathol.* 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14. PMID: 35288841.

22: Yuan H, Wu Y, Wang J, Qin X, Huang Y, Yan L, Fana Y, Zedenius J, **Juhlin CC**, Larsson C, Lui WO, Xu D. Synergistic effects of telomerase reverse transcriptase and regulator of telomere elongation helicase 1 on aggressiveness and outcomes in adrenocortical carcinoma. *Biomed Pharmacother.* 2022 May;149:112796. doi: 10.1016/j.biopha.2022.112796. Epub 2022 Mar 10. PMID: 35279598.

23: Calissendorff J, **Juhlin CC**, Bancos I, Falhammar H. Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance. *Cancers (Basel).* 2022 Feb 12;14(4):917. doi: 10.3390/cancers14040917. PMID: 35205664; PMCID: PMC8869962.

24: Erickson LA, Mete O, **Juhlin CC**, Perren A, Gill AJ. Overview of the 2022 WHO Classification of Parathyroid Tumors. *Endocr Pathol.* 2022 Mar;33(1):64-89. doi: 10.1007/s12022-022-09709-1. Epub 2022 Feb 17. PMID: 35175514.

25: Stenman A, Kjellman M, Zedenius J, **Juhlin CC**. Synchronous lateral lymph node metastases from papillary and follicular thyroid carcinoma: case report and review of the literature. *Thyroid Res.* 2022 Feb 4;15(1):1. doi: 10.1186/s13044-022-00120-w. PMID: 35120551; PMCID: PMC8815265.

26: Steen S, Hysek M, Zedenius J, Falhammar H, **Juhlin CC**. Cyto-morphological features of parathyroid lesions: Fine-needle aspiration cytology series from an endocrine tumor referral center. *Diagn Cytopathol.* 2022 Feb;50(2):75-83. doi: 10.1002/dc.24923. Epub 2021 Dec 27. PMID: 34962106.

27: Stenman A, Yang M, Paulsson JO, Zedenius J, Paulsson K, **Juhlin CC**. Pan-Genomic Sequencing Reveals Actionable *CDKN2A/2B* Deletions and Kataegis in Anaplastic Thyroid Carcinoma. *Cancers (Basel).* 2021 Dec 17;13(24):6340. doi: 10.3390/cancers13246340. PMID: 34944959; PMCID: PMC8699293.

28: Gao J, Shi H, **Juhlin CC**, Larsson C, Lui WO. Merkel cell polyomavirus T-antigens regulate *DICER1* mRNA stability and translation through HSC70. *iScience.* 2021 Oct 14;24(11):103264. doi: 10.1016/j.isci.2021.103264. PMID: 34761184; PMCID: PMC8567380.

29: Paulsson JO, Zedenius J, **Juhlin CC**. TERT Promoter Mutated Follicular Thyroid Carcinomas Exhibit a Distinct microRNA Expressional Profile with Potential Implications for Tumor Progression. *Endocr Pathol.* 2021 Dec;32(4):513-516. doi: 10.1007/s12022-021-09695-w. Epub 2021 Oct 21. PMID: 34676499; PMCID: PMC8608760.

30: **Juhlin CC**. Second-Generation Neuroendocrine Immunohistochemical Markers: Reflections from Clinical Implementation. *Biology (Basel)*. 2021 Sep 5;10(9):874. doi: 10.3390/biology10090874. PMID: 34571751; PMCID: PMC8467755.

31: Bedoya-Reina OC, Li W, Arceo M, Plescher M, Bullova P, Pui H, Kaucka M, Kharchenko P, Martinsson T, Holmberg J, Adameyko I, Deng Q, Larsson C, Juhlin CC, Kogner P, Schlisio S. Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors. *Nat Commun*. 2021 Sep 7;12(1):5309. doi: 10.1038/s41467-021-24870-7. PMID: 34493726; PMCID: PMC8423786.

32: Calissendorff J, **Juhlin CC**, Sundin A, Bancos I, Falhammar H. Adrenal myelolipomas. *Lancet Diabetes Endocrinol*. 2021 Nov;9(11):767-775. doi: 10.1016/S2213-8587(21)00178-9. Epub 2021 Aug 24. PMID: 34450092; PMCID: PMC8851410.

33: **Juhlin CC**, Zedenius J. Parathyroid Adenoma With Respiratory-Like Epithelium: Case Report of a Potential Mimic With Unknown Etiology. *Front Endocrinol (Lausanne)*. 2021 Aug 4;12:724766. doi: 10.3389/fendo.2021.724766. PMID: 34421830; PMCID: PMC8371401.

34: Johansson K, Stenman A, Paulsson JO, Wang N, Ihre-Lundgren C, Zedenius J, **Juhlin CC**. Development of metastatic poorly differentiated thyroid cancer from a sub-centimeter papillary thyroid carcinoma in a young patient with a germline

Christofer Juhlin, 791009-5632

MET mutation - association or random chance? *Thyroid Res.* 2021 Aug 14;14(1):19.

doi: 10.1186/s13044-021-00110-4. PMID: 34389035; PMCID: PMC8364030.

35: Nilsson JN, Siikanen J, Hedman C, **Juhlin CC**, Ihre Lundgren C. Pre-

Therapeutic Measurements of Iodine Avidity in Papillary and Poorly

Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression,

Histological Variants and Ki-67 Index. *Cancers (Basel)*. 2021 Jul 20;13(14):3627.

doi: 10.3390/cancers13143627. PMID: 34298840; PMCID: PMC8307105.

36: Paulsson JO, Rafati N, DiLorenzo S, Chen Y, Haglund F, Zedenius J, Juhlin

CC. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent

Mutations in MicroRNA Processing Subunit DGCR8. *J Clin Endocrinol Metab.* 2021

Oct 21;106(11):3265-3282. doi: 10.1210/clinem/dgab471. PMID: 34171097; PMCID:

PMC8530729.

37: Hellgren LS, Olsson A, Kaufeldt A, Paulsson JO, Hysek M, Stenman A, Zedenius

J, Larsson C, Höög A, **Juhlin CC**. Nuclear-specific accumulation of telomerase

reverse transcriptase (*TERT*) mRNA in *TERT* promoter mutated

follicular thyroid tumours visualised by in situ hybridisation: a possible

clinical screening tool? *J Clin Pathol.* 2021 May 19;75(10):658–62. doi:

10.1136/jclinpath-2021-207631. Epub ahead of print. PMID: 34011619; PMCID:

PMC9510436.

38: **Juhlin CC**, Stenman A, Zedenius J. Macrofollicular variant follicular thyroid

tumors are DICER1 mutated and exhibit distinct histological features.

Christofer Juhlin, 791009-5632

Histopathology. 2021 Oct;79(4):661-666. doi: 10.1111/his.14416. Epub 2021 Aug 3.

PMID: 34008223.

39: **Juhlin CC**, Nilsson IL, Falhammar H, Zedenius J. Institutional

characterisation of water clear cell parathyroid adenoma: a rare entity often

unrecognised by TC-99m-sestamibi scintigraphy. Pathology. 2021

Dec;53(7):852-859. doi: 10.1016/j.pathol.2021.02.011. Epub 2021 May 14. PMID:

33994174.

40: Calissendorff J, Bjellerup-Calissendorff F, Bränström R, **Juhlin CC**,

Falhammar H. Characteristics, Treatment, Outcomes, and Survival in

Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary

Referral Center. Front Endocrinol (Lausanne). 2021 Apr 13;12:657698. doi:

10.3389/fendo.2021.657698. PMID: 33927695; PMCID: PMC8076901.

41: Stenman A, Backman S, Johansson K, Paulsson JO, Stålberg P, Zedenius J,

Juhlin CC. Pan-genomic characterization of high-risk pediatric papillary thyroid

carcinoma. Endocr Relat Cancer. 2021 Apr 29;28(5):337-351. doi:

10.1530/ERC-20-0464. PMID: 33827048; PMCID: PMC8111328.

42: Lindfors H, Ihre Lundgren C, Zedenius J, **Juhlin CC**, Shabo I. The Clinical

Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid

Cancer. World J Surg. 2021 Jul;45(7):2155-2164. doi: 10.1007/s00268-021-06070-y.

Epub 2021 Apr 7. PMID: 33825961; PMCID: PMC8154824.

Christofer Juhlin, 791009-5632

43: **Juhlin CC**. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry. *Endocr Pathol*. 2021 Jun;32(2):228-244. doi: 10.1007/s12022-021-09675-0. Epub 2021 Mar 25. PMID: 33768452; PMCID: PMC8116282.

44: Stergianos S, **Juhlin CC**, Zedenius J, Calissendorff J, Falhammar H. Metastasis to the thyroid gland: Characterization and survival of an institutional series spanning 28 years. *Eur J Surg Oncol*. 2021 Jun;47(6):1364-1369. doi: 10.1016/j.ejso.2021.02.018. Epub 2021 Feb 19. PMID: 33642087.

45: Shi Y, Yuan J, Rraklli V, Maxymovitz E, Cipullo M, Liu M, Li S, Westerlund I, Bedoya-Reina OC, Bullova P, Rorbach J, **Juhlin CC**, Stenman A, Larsson C, Kogner P, O'Sullivan MJ, Schlisio S, Holmberg J. Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors. *Nucleic Acids Res*. 2021 Mar 18;49(5):2509-2521. doi: 10.1093/nar/gkab054. PMID: 33555349; PMCID: PMC7969022.

46: **Juhlin CC**, Bertherat J, Giordano TJ, Hammer GD, Sasano H, Mete O. What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. *Endocr Pathol*. 2021 Mar;32(1):102-133. doi: 10.1007/s12022-021-09667-0. Epub 2021 Feb 3. PMID: 33534120.

47: Stenman A, Koman A, Ihre-Lundgren C, **Juhlin CC**. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene

Christofer Juhlin, 791009-5632

homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report. *Medicine (Baltimore)*. 2021 Jan 15;100(2):e24237. doi: 10.1097/MD.00000000000024237. PMID: 33466206; PMCID: PMC7808519.

48: Granberg D, **Juhlin CC**, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. *J Clin Endocrinol Metab*. 2021 Apr 23;106(5):e1937-e1952. doi: 10.1210/clinem/dgaa982. PMID: 33462603; PMCID: PMC8063253.

49: **Juhlin CC**, Erickson LA. Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice. *Endocr Pathol*. 2021 Mar;32(1):17-34. doi: 10.1007/s12022-020-09656-9. Epub 2020 Dec 2. PMID: 33269427; PMCID: PMC7960610.

50: Bancos I, Atkinson E, Eng C, Young WF Jr, Neumann HPH; International Pheochromocytoma and Pregnancy Study Group. Maternal and fetal outcomes in pheochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. *Lancet Diabetes Endocrinol*. 2021 Jan;9(1):13-21. doi: 10.1016/S2213-8587(20)30363-6. Epub 2020 Nov 26. PMID: 33248478; PMCID: PMC7758862.

51: Hysek M, Jatta K, Hellgren LS, Stenman A, Larsson C, Zedenius J, **Juhlin CC**. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the

Christofer Juhlin, 791009-5632

Digital Droplet PCR Technique. *J Mol Diagn.* 2021 Feb;23(2):212-222. doi:

10.1016/j.jmoldx.2020.10.016. Epub 2020 Nov 14. PMID: 33197629.

52: **Juhlin CC**. Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms? *Cancer Drug Resist.* 2020 Nov 3;3(4):992-1000. doi: 10.20517/cdr.2020.66. PMID: 35582231; PMCID: PMC8992567.

53: Nicolson NG, Paulsson JO, **Juhlin CC**, Carling T, Korah R. Transcription Factor Profiling Identifies Spatially Heterogenous Mediators of Follicular Thyroid Cancer Invasion. *Endocr Pathol.* 2020 Dec;31(4):367-376. doi: 10.1007/s12022-020-09651-0. Epub 2020 Oct 16. PMID: 33063251; PMCID: PMC7666283.

54: **Juhlin CC**, Falhammar H, Kjellman M, Åhlén J, Welin S, Calissendorff J. Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission. *BMC Gastroenterol.* 2020 Aug 27;20(1):290. doi: 10.1186/s12876-020-01433-6. PMID: 32854635; PMCID: PMC7457256.

55: **Juhlin CC**, Zedenius J, Höög A. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagoin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin. *Endocr Pathol.* 2020 Dec;31(4):401-410. doi: 10.1007/s12022-020-09645-y. Epub 2020 Aug 19. PMID: 32813226; PMCID: PMC7665972.

56: Xing X, Mu N, Yuan X, Wang N, **Juhlin CC**, Strååt K, Larsson C, Xu D. PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid Carcinoma. *Cancers (Basel)*. 2020 Jul 31;12(8):2133. doi: 10.3390/cancers12082133. PMID: 32752127; PMCID: PMC7465481.

57: Hellgren LS, Hysek M, Jatta K, Zedenius J, **Juhlin CC**. Macrofollicular Variant of Follicular Thyroid Carcinoma (MV-FTC) with a Somatic DICER1 Gene Mutation: Case Report and Review of the Literature. *Head Neck Pathol*. 2021 Jun;15(2):668-675. doi: 10.1007/s12105-020-01208-1. Epub 2020 Jul 25. PMID: 32712880; PMCID: PMC8134796.

58: Zala A, Berhane T, **Juhlin CC**, Calissendorff J, Falhammar H. Riedel Thyroiditis. *J Clin Endocrinol Metab*. 2020 Sep 1;105(9):dgaa468. doi: 10.1210/clinem/dgaa468. PMID: 32687163.

59: Brown TC, Nicolson NG, Man J, Gibson CE, Stenman A, **Juhlin CC**, Korah R, Carling T. Recurrent Amplification of the Osmotic Stress Transcription Factor *NFAT5* in Adrenocortical Carcinoma. *J Endocr Soc*. 2020 May 25;4(7):bvaa060. doi: 10.1210/jendso/bvaa060. PMID: 32587934; PMCID: PMC7304660.

60: **Juhlin CC**, Asa SL, Jatta K, Naserhojati Rodsari H, Shabo I, Haglund F, Delahunt B, Samaratunga H, Egevad L, Höög A, Zedenius J. Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. *Head Neck Pathol*. 2021 Jun;15(2):628-637. doi:

Christofer Juhlin, 791009-5632

10.1007/s12105-020-01187-3. Epub 2020 Jun 9. PMID: 32519264; PMCID: PMC8134583.

61: **Juhlin CC**, Zedenius J, Haglund F. Metastatic malignant melanoma with neuroendocrine differentiation: a case report and review of the literature. *J Med Case Rep.* 2020 Mar 31;14(1):44. doi: 10.1186/s13256-020-02367-z. PMID: 32234068; PMCID: PMC7110723.

62: **Juhlin CC**, Falhammar H, Zedenius J, Nilsson IL, Höög A. Lipoadenoma of the Parathyroid Gland: Characterization of an Institutional Series Spanning 28 Years. *Endocr Pathol.* 2020 Jun;31(2):156-165. doi: 10.1007/s12022-020-09616-3. PMID: 32193823; PMCID: PMC7250804.

63: Paulsson JO, Wang N, Gao J, Stenman A, Zedenius J, Mu N, Lui WO, Larsson C, **Juhlin CC**. GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours. *Endocr Relat Cancer.* 2020 May;27(5):295-308. doi: 10.1530/ERC-19-0446. PMID: 32163919; PMCID: PMC7159166.

64: **Juhlin CC**, Skoglund S, Juntti-Berggren L, Karlberg M, Calissendorff J. Non-functioning neuroendocrine pancreatic tumors transforming to malignant insulinomas - four cases and review of the literature. *Neuro Endocrinol Lett.* 2019 Nov;40(4):175-183. PMID: 32087093.

65: Stenman A, Hellgren LS, Jatta K, Hysek M, Zemmler M, Altena R, Nilsson IL, Bränström R, Zedenius J, **Juhlin CC**. Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare

Christofer Juhlin, 791009-5632

Case. Endocr Pathol. 2020 Mar;31(1):77-83. doi: 10.1007/s12022-020-09606-5.

PMID: 32016808.

66: Hysek M, Jatta K, Stenman A, Darai-Ramqvist E, Zedenius J, Höög A, Juhlin

CC. Signet ring cell variant of follicular thyroid carcinoma: Report of two

cases with focus on morphological, expressional and genetic characteristics.

Diagn Pathol. 2019 Nov 7;14(1):127. doi: 10.1186/s13000-019-0904-3. PMID:

31699114; PMCID: PMC6839064.

67: Stenman A, Shabo I, Ramström A, Zedenius J, **Juhlin CC**. Synchronous

aldosterone- and cortisol-producing adrenocortical adenomas diagnosed using

CYP11B immunohistochemistry. SAGE Open Med Case Rep. 2019 Oct

18;7:2050313X19883770. doi: 10.1177/2050313X19883770. PMID: 31666955; PMCID:

PMC6801880.

68: Paulsson JO, Backman S, Wang N, Stenman A, Crona J, Thutkawkorapin J,

Ghaderi M, Tham E, Stålberg P, Zedenius J, **Juhlin CC**. Whole-genome sequencing of

synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer

dedifferentiation. J Pathol. 2020 Feb;250(2):183-194. doi: 10.1002/path.5359.

Epub 2019 Nov 29. PMID: 31621921.

69: Hysek M, Paulsson JO, Jatta K, Shabo I, Stenman A, Höög A, Larsson C,

Zedenius J, **Juhlin CC**. Clinical Routine *TERT* Promoter Mutational

Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-

UMPs): A Useful Predictor of Metastatic Disease. Cancers (Basel). 2019 Sep

Christofer Juhlin, 791009-5632

26;11(10):1443. doi: 10.3390/cancers11101443. PMID: 31561592; PMCID: PMC6826397.

70: Fotouhi O, Kjellin H, **Juhlin CC**, Pan Y, Vesterlund M, Ghaderi M, Yousef A, Andersson-Sand H, Kharaziha P, Caramuta S, Kjellman M, Zedenius J, Larsson C, Orre LM. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors. *Oncogene*. 2019 Oct;38(43):6881-6897. doi: 10.1038/s41388-019-0938-8. Epub 2019 Aug 12. PMID: 31406256.

71: Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, Kaur RJ, McKenzie T, Qi X, Bandgar T, Petrov R, Yukina MY, Roslyakova A, van der Horst-Schrivers ANA, Berends AMA, Hoff AO, Castroneves LA, Ferrara AM, Rizzati S, Mian C, Dvorakova S, Hasse-Lazar K, Kvachenyuk A, Peczkowska M, Loli P, Erenler F, Krauss T, Almeida MQ, Liu L, Zhu F, Recasens M, Wohllk N, Corssmit EPM, Shafigullina Z, Calissendorff J, Grozinsky-Glasberg S, Kunavisarut T, Schalin-Jääntti C, Castinetti F, Vlcek P, Beltsevich D, Egorov VI, Schiavi F, Links TP, Lechan RM, Bausch B, Young WF Jr, Eng C; International Bilateral-Pheochromocytoma-Registry Group. Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. *JAMA Netw Open*. 2019 Aug 2;2(8):e198898. doi: 10.1001/jamanetworkopen.2019.8898. PMID: 31397861; PMCID: PMC6692838.

72: Falhammar H, Stenman A, Calissendorff J, **Juhlin CC**. Presentation, Treatment, Histology, and Outcomes in Adrenal Medullary Hyperplasia Compared With Pheochromocytoma. *J Endocr Soc*. 2019 Jun 11;3(8):1518-1530. doi:

Christofer Juhlin, 791009-5632

10.1210/js.2019-00200. PMID: 31384714; PMCID: PMC6676072.

73: Li S, Rodriguez J, Li W, Bullova P, Fell SM, Surova O, Westerlund I, Topcic D, Bergsland M, Stenman A, Muhr J, Nistér M, Holmberg J, **Juhlin CC**, Larsson C, von Kriegsheim A, Kaelin WG Jr, Schlisio S. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. *Proc Natl Acad Sci U S A*. 2019 Aug 20;116(34):16997-17006. doi: 10.1073/pnas.1900748116. Epub 2019 Aug 2. PMID: 31375625; PMCID: PMC6708352.

74: Fotouhi O, Ghaderi M, Wang N, Zedenius J, Kjellman M, Xu D, **Juhlin CC**, Larsson C. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant *TERT* promoter methylation, but not hot-spot mutations. *Epigenetics*. 2019 Dec;14(12):1224-1233. doi: 10.1080/15592294.2019.1634987. Epub 2019 Jul 19. PMID: 31322481; PMCID: PMC6791720.

75: Stenman A, Zedenius J, **Juhlin CC**. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up. *Surgery*. 2019 Nov;166(5):901-906. doi: 10.1016/j.surg.2019.04.030. Epub 2019 Jun 22. PMID: 31239074.

76: **Juhlin CC**, Stenman A, Zedenius J. Incidensökning av endokrina tumörer - Kraftig ökning av diagnostiserade tumörer i sköldkörtel, bisköldkörtel och binjure i stockholm mellan 1992 och 2017 [Endocrine tumours in Stockholm -

Christofer Juhlin, 791009-5632

increasing general incidence]. *Lakartidningen*. 2019 Mar 12;116:FHM3. Swedish.

PMID: 31192414.

77: Kumar S, Xie H, Shi H, Gao J, **Juhlin CC**, Björnhagen V, Höög A, Lee L, Larsson C, Lui WO. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes. *Int J Cancer*. 2020 Mar 15;146(6):1652-1666. doi: 10.1002/ijc.32503. Epub 2019 Jun 20. PMID: 31180579; PMCID: PMC7003823.

78: Stenman A, Hysek M, Jatta K, Bränström R, Darai-Ramqvist E, Paulsson JO, Wang N, Larsson C, Zedenius J, **Juhlin CC**. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up. *Endocr Pathol*. 2019 Sep;30(3):246-248. doi: 10.1007/s12022-019-09580-7. PMID: 31154561.

79: **Juhlin CC**. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert! *Scand J Surg*. 2020 Sep;109(3):187-192. doi: 10.1177/1457496919850434. Epub 2019 May 26. PMID: 31131695.

80: Brown TC, Nicolson NG, Stenman A, **Juhlin CC**, Gibson CE, Callender GG, Korah R, Carling T. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma. *J Am Coll Surg*. 2019 Sep;229(3):305-315. doi: 10.1016/j.jamcollsurg.2019.04.018. Epub 2019 Apr 26. PMID: 31034883.

Christofer Juhlin, 791009-5632

81: **Juhlin CC**, Höög A. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case. *Int J Surg Pathol*. 2019 Sep;27(6):658-663. doi: 10.1177/1066896919837678. Epub 2019 Apr 1. PMID: 30931661.

82: **Juhlin CC**, Nilsson IL, Lagerstedt-Robinson K, Stenman A, Bränström R, Tham E, Höög A. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. *Mod Pathol*. 2019 Jul;32(8):1082-1094. doi: 10.1038/s41379-019-0252-6. Epub 2019 Mar 28. PMID: 30923346.

83: Stenman A, Zedenius J, **Juhlin CC**. The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature. *Cancers (Basel)*. 2019 Feb 15;11(2):225. doi: 10.3390/cancers11020225. PMID: 30769931; PMCID: PMC6406721.

84: Volpe C, Hamberger B, Zedenius J, **Juhlin CC**. Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism: An important tool for improved patient follow-up. *Scand J Surg*. 2020 Jun;109(2):133-142. doi: 10.1177/1457496918822622. Epub 2019 Jan 17. PMID: 30654730.

85: Fotouhi O, Zedenius J, Höög A, **Juhlin CC**. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors. *Neuro Endocrinol Lett*. 2018

Christofer Juhlin, 791009-5632

Oct;39(4):305-309. PMID: 30531706.

86: Stenman A, Svahn F, Hojjat-Farsangi M, Zedenius J, Söderkvist P, Gimm O, Larsson C, **Juhlin CC**. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. *Am J Surg Pathol*. 2019 Mar;43(3):409-421. doi: 10.1097/PAS.0000000000001190. PMID: 30451732.

87: **Juhlin CC**, Bränström R, Shabo I, Höög A. Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report. *Int J Surg Pathol*. 2019 May;27(3):290-293. doi: 10.1177/1066896918809490. Epub 2018 Oct 29. PMID: 30370813.

88: Paulsson JO, Olander A, Haglund F, Zedenius J, **Juhlin CC**. TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma. *Endocr Pathol*. 2018 Dec;29(4):380-383. doi: 10.1007/s12022-018-9551-6. PMID: 30306386; PMCID: PMC6223712.

89: Yuan X, Mu N, Wang N, Strååt K, Sofiadis A, Guo Y, Stenman A, Li K, Cheng G, Zhang L, Kong F, Ekblad L, Wennerberg J, Nilsson IL, **Juhlin CC**, Larsson C, Xu D. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression. *Oncogene*. 2019 Feb;38(7):965-979. doi: 10.1038/s41388-018-0483-x. Epub 2018 Sep 4. PMID: 30181547.

Christofer Juhlin, 791009-5632

90: **Juhlin CC**, Nilsson IL, Höög A. Solid Cell Nests Within a Parathyroid Gland-
Report of an Exceptional Case. *Endocr Pathol.* 2018 Dec;29(4):365-368. doi:

10.1007/s12022-018-9539-2. PMID: 30003532; PMCID: PMC6223718.

91: Paulsson JO, Zedenius J, **Juhlin CC**. Papillary thyroid carcinoma with
pleomorphic tumor giant cells in a pregnant woman - a case report. *BMC Endocr
Disord.* 2018 Jul 5;18(1):46. doi: 10.1186/s12902-018-0275-x. PMID: 29976183;
PMCID: PMC6034243.

92: Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, Korah R,
Carling T, Bäckdahl M, Wang N, **Juhlin CC**, Larsson C. TERT promoter
hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Int J Mol Med. 2018 Sep;42(3):1675-1683. doi: 10.3892/ijmm.2018.3735. Epub 2018
Jun 20. PMID: 29956721.

93: Hysek M, Paulsson JO, Wang N, Jatta K, Lindh C, Fuentes-Martinez N, Shabo I,
Zedenius J, **Juhlin CC**. TERT promoter mutational screening as a tool to predict
malignant behaviour in follicular thyroid tumours-three examples from the
clinical routine. *Virchows Arch.* 2018 Nov;473(5):639-643. doi:
10.1007/s00428-018-2386-1. Epub 2018 Jun 2. PMID: 29860621.

94: Lolis E, **Juhlin CC**, Nordenström A, Falhammar H. Extensive Bilateral Adrenal
Rest Testicular Tumors in a Patient With 3α -Hydroxysteroid Dehydrogenase
Type 2 Deficiency. *J Endocr Soc.* 2018 May 1;2(6):513-517. doi:
10.1210/js.2018-00082. PMID: 29850650; PMCID: PMC5961024.

95: Mu N, **Juhlin CC**, Tani E, Sofiadis A, Reihner E, Zedenius J, Larsson C, Nilsson IL. High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma. *Endocrine*. 2018 Aug;61(2):293-302. doi: 10.1007/s12020-018-1627-z. Epub 2018 May 23. PMID: 29796987; PMCID: PMC6061212.

96: Stenman A, Zedenius J, **Juhlin CC**. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms. *Langenbecks Arch Surg*. 2018 Sep;403(6):785-790. doi: 10.1007/s00423-018-1679-9. Epub 2018 May 19. PMID: 29779047; PMCID: PMC6153590.

97: Nicolson NG, Murtha TD, Dong W, Paulsson JO, Choi J, Barbieri AL, Brown TC, Kunstman JW, Larsson C, Prasad ML, Korah R, Lifton RP, **Juhlin CC**, Carling T. Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology. *J Clin Endocrinol Metab*. 2018 Jul 1;103(7):2640-2650. doi: 10.1210/jc.2018-00277. PMID: 29726952.

98: Paulsson JO, Mu N, Shabo I, Wang N, Zedenius J, Larsson C, **Juhlin CC**. *TERT* aberrancies: a screening tool for malignancy in follicular thyroid tumours. *Endocr Relat Cancer*. 2018 Jul;25(7):723-733. doi: 10.1530/ERC-18-0050. Epub 2018 Apr 24. PMID: 29692346.

99: Höög A, Kjellman M, Mattsson P, **Juhlin CC**, Shabo I. Somatostatin Receptor Expression in Renal Cell Carcinoma-A New Front in the Diagnostics and Treatment

Christofer Juhlin, 791009-5632

of Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2018 Jun;16(3):e517-e520. doi: 10.1016/j.clgc.2018.03.011. Epub 2018 Mar 27. PMID: 29656940.

100: Falhammar H, **Juhlin CC**, Barner C, Catrina SB, Karefylakis C, Calissendorff J. Riedel's thyroiditis: clinical presentation, treatment and outcomes. *Endocrine*. 2018 Apr;60(1):185-192. doi: 10.1007/s12020-018-1526-3. Epub 2018 Jan 29. PMID: 29380231; PMCID: PMC5845586.

101: Svahn F, **Juhlin CC**, Paulsson JO, Fotouhi O, Zedenius J, Larsson C, Stenman A. Telomerase reverse transcriptase promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma. *Clin Endocrinol (Oxf)*. 2018 Feb;88(2):343-345. doi: 10.1111/cen.13513. Epub 2017 Nov 27. PMID: 29130501.

102: Haglund F, Hallström BM, Nilsson IL, Höög A, **Juhlin CC**, Larsson C. Inflammatory infiltrates in parathyroid tumors. *Eur J Endocrinol*. 2017 Dec;177(6):445-453. doi: 10.1530/EJE-17-0277. Epub 2017 Aug 30. PMID: 28855268; PMCID: PMC5642267.

103: Özata DM, Li X, Lee L, Liu J, Warsito D, Hajeri P, Hultman I, Fotouhi O, Marklund S, Ährlund-Richter L, **Juhlin CC**, Larsson C, Lui WO. Loss of miR-514a-3p regulation of PEG3 activates the NF-kappa B pathway in human testicular germ cell tumors. *Cell Death Dis*. 2017 May 4;8(5):e2759. doi: 10.1038/cddis.2016.464. PMID: 28471449; PMCID: PMC5520681.

104: Cheng JY, Brown TC, Murtha TD, Stenman A, **Juhlin CC**, Larsson C, Healy JM,

Christofer Juhlin, 791009-5632

Prasad ML, Knoefel WT, Krieg A, Scholl UI, Korah R, Carling T. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis. *BMC Cancer*. 2017 Mar 1;17(1):164. doi: 10.1186/s12885-017-3152-5. PMID: 28249601; PMCID: PMC5333434.

105: Murtha TD, Brown TC, Rubinstein JC, Haglund F, **Juhlin CC**, Larsson C, Korah R, Carling T. Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma. *Surgery*. 2017 Jun;161(6):1667-1674. doi: 10.1016/j.surg.2016.11.036. Epub 2017 Jan 7. PMID: 28073588; PMCID: PMC7301492.

106: Nolé P, Duijndam B, Stenman A, **Juhlin CC**, Kozyra M, Larsson C, Ingelman-Sundberg M, Johansson I. Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas. *PLoS One*. 2016 Sep 6;11(9):e0162379. doi: 10.1371/journal.pone.0162379. PMID: 27598485; PMCID: PMC5012573.

107: Rubinstein JC, Brown TC, Christison-Lagay ER, Zhang Y, Kunstman JW, Juhlin CC, Nelson-Williams C, Goh G, Quinn CE, Callender GG, Udelsman R, Lifton RP, Korah R, Carling T. Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma. *BMC Cancer*. 2016 Aug 18;16:646. doi: 10.1186/s12885-016-2665-7. PMID: 27538953; PMCID: PMC4989347.

108: Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, **Juhlin CC**, Lu M, Höög A, Pastrían LG, Lamarca A, Soto VH, Zedenius J, Mendiola M, Lehtiö J, Kjellman M. Proteomics Suggests a Role for APC-Survivin in Response to

Christofer Juhlin, 791009-5632

Somatostatin Analog Treatment of Neuroendocrine Tumors. *J Clin Endocrinol Metab.* 2016 Oct;101(10):3616-3627. doi: 10.1210/jc.2016-2028. Epub 2016 Jul 26. PMID: 27459532; PMCID: PMC5052342.

109: Haglund F, Garvin S, Ihre-Lundgren C, Nilsson IL, Hall E, Carling T, Höög A, **Juhlin CC**. Detailed Lymph Node Sectioning of Papillary Thyroid Carcinoma Specimen Increases the Number of pN1a Patients. *Endocr Pathol.* 2016 Dec;27(4):346-351. doi: 10.1007/s12022-016-9438-3. PMID: 27251056.

110: Wang N, Kjellin H, Sofiadis A, Fotouhi O, **Juhlin CC**, Bäckdahl M, Zedenius J, Xu D, Lehtiö J, Larsson C. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. *Oncotarget.* 2016 Apr 19;7(16):21332-46. doi: 10.18632/oncotarget.7237. PMID: 26870890; PMCID: PMC5008288.

111: Haglund F, **Juhlin CC**, Kiss NB, Larsson C, Nilsson IL, Höög A. Diffuse parathyroid hormone expression in parathyroid tumors argues against important functional tumor subclones. *Eur J Endocrinol.* 2016 May;174(5):583-90. doi: 10.1530/EJE-15-1062. Epub 2016 Feb 10. PMID: 26865585; PMCID: PMC5081673.

112: Stenson G, Nilsson IL, Mu N, Larsson C, Lundgren CI, **Juhlin CC**, Höög A, Zedenius J. Minimally invasive follicular thyroid carcinomas: prognostic factors. *Endocrine.* 2016 Aug;53(2):505-11. doi: 10.1007/s12020-016-0876-y. Epub 2016 Feb 8. PMID: 26858184; PMCID: PMC4949299.

Christofer Juhlin, 791009-5632

113: Stenman A, Welander J, Gustavsson I, Brunaud L, Bäckdahl M, Söderkvist P, Gimm O, **Juhlin CC**, Larsson C. HRAS mutation prevalence and associated expression patterns in pheochromocytoma. *Genes Chromosomes Cancer*. 2016 May;55(5):452-9. doi: 10.1002/gcc.22347. Epub 2016 Feb 23. PMID: 26773571; PMCID: PMC4794776.

114: Paulsson JO, Svahn F, Welander J, Brunaud L, Söderkvist P, Gimm O, Stenman A, **Juhlin CC**. Absence of the BRAF V600E mutation in pheochromocytoma. *J Endocrinol Invest*. 2016 Jun;39(6):715-6. doi: 10.1007/s40618-015-0420-6. Epub 2015 Dec 28. PMID: 26710756.

115: Brown TC, **Juhlin CC**, Healy JM, Stenman A, Rubinstein JC, Korah R, Carling T. DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma. *Surgery*. 2016 Jan;159(1):250-7. doi: 10.1016/j.surg.2015.08.038. Epub 2015 Oct 9. PMID: 26454676; PMCID: PMC7249607.

116: Rubinstein JC, Brown TC, Goh G, **Juhlin CC**, Stenman A, Korah R, Carling T. Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma. *Surgery*. 2016 Jan;159(1):296-301. doi: 10.1016/j.surg.2015.09.001. Epub 2015 Oct 6. PMID: 26453132.

117: Stenman A, **Juhlin CC**, Haglund F, Brown TC, Clark VE, Svahn F, Bilguvar K, Goh G, Korah R, Lifton RP, Carling T. Absence of KMT2D/MLL2 mutations in abdominal paraganglioma. *Clin Endocrinol (Oxf)*. 2016 Apr;84(4):632-4. doi: 10.1111/cen.12884. Epub 2015 Sep 22. PMID: 26303934.

Christofer Juhlin, 791009-5632

118: **Juhlin CC**, Stenman A, Haglund F, Clark VE, Brown TC, Baranoski J, Bilguvar K, Goh G, Welander J, Svahn F, Rubinstein JC, Caramuta S, Yasuno K, Günel M, Bäckdahl M, Gimm O, Söderkvist P, Prasad ML, Korah R, Lifton RP, Carling T. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene. *Genes Chromosomes Cancer*. 2015 Sep;54(9):542-54. doi: 10.1002/gcc.22267. Epub 2015 May 29. PMID: 26032282; PMCID: PMC4755142.

119: Dinets A, Pernemalm M, Kjellin H, Sviatoha V, Sofiadis A, **Juhlin CC**, Zedenius J, Larsson C, Lehtiö J, Höög A. Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions. *PLoS One*. 2015 May 15;10(5):e0126472. doi: 10.1371/journal.pone.0126472. PMID: 25978681; PMCID: PMC4433121.

120: Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, **Juhlin CC**, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. *Elife*. 2015 Apr 24;4:e06315. doi: 10.7554/eLife.06315. PMID: 25907736; PMCID: PMC4408447.

121: Haglund F, **Juhlin CC**, Brown T, Ghaderi M, Liu T, Stenman A, Dinets A, Prasad M, Korah R, Xu D, Carling T, Larsson C. TERT promoter mutations are rare in parathyroid tumors. *Endocr Relat Cancer*. 2015 Jun;22(3):L9-L11. doi: 10.1530/ERC-15-0121. Epub 2015 Apr 15. PMID: 25876648.

122: Haglund F, Rosin G, Nilsson IL, **Juhlin CC**, Pernow Y, Norenstedt S, Dinets A, Larsson C, Hartman J, Höög A. Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight. *Endocr Connect.* 2015 Mar;4(1):76-85. doi: 10.1530/EC-14-0109. Epub 2015 Feb 3. PMID: 25648860; PMCID: PMC4351559.

123: Kunstman JW, **Juhlin CC**, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. *Hum Mol Genet.* 2015 Apr 15;24(8):2318-29. doi: 10.1093/hmg/ddu749. Epub 2015 Jan 9. PMID: 25576899; PMCID: PMC4380073.

124: **Juhlin CC**, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. *J Clin Endocrinol Metab.* 2015 Mar;100(3):E493-502. doi: 10.1210/jc.2014-3282. Epub 2014 Dec 9. PMID: 25490274; PMCID: PMC5393505.

125: Stenman A, Svahn F, Welander J, Gustavson B, Söderkvist P, Gimm O, Juhlin CC. Immunohistochemical NF1 analysis does not predict NF1 gene mutation status in pheochromocytoma. *Endocr Pathol.* 2015 Mar;26(1):9-14. doi:

Christofer Juhlin, 791009-5632

10.1007/s12022-014-9348-1. PMID: 25403449.

126: Carlsson AC, **Juhlin CC**, Larsson TE, Larsson A, Ingelsson E, Sundström J, Lind L, Arnlöv J. Soluble tumor necrosis factor receptor 1 (sTNFR1) is associated with increased total mortality due to cancer and cardiovascular causes - findings from two community based cohorts of elderly. *Atherosclerosis*. 2014 Nov;237(1):236-42. doi: 10.1016/j.atherosclerosis.2014.09.005. Epub 2014 Sep 16. PMID: 25255422.

127: Brown TC, **Juhlin CC**, Healy JM, Prasad ML, Korah R, Carling T. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis. *JAMA Surg*. 2014 Nov;149(11):1146-52. doi: 10.1001/jamasurg.2014.1694. PMID: 25229773.

128: Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminsky VO, **Juhlin CC**, Höög A, Bodin I, Svjatoha V, Larsson C, Zedenius J, Wennerberg J, Lundqvist A. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. *Clin Cancer Res*. 2014 Nov 15;20(22):5733-44. doi: 10.1158/1078-0432.CCR-14-0291. Epub 2014 Sep 11. PMID: 25212604.

129: Wang N, Liu T, Sofiadis A, **Juhlin CC**, Zedenius J, Höög A, Larsson C, Xu D. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. *Cancer*. 2014 Oct

Christofer Juhlin, 791009-5632

1;120(19):2965-79. doi: 10.1002/cncr.28800. Epub 2014 Jun 4. PMID: 24898513.

130: Liu T, Brown TC, **Juhlin CC**, Andreasson A, Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, Xu D, Larsson C. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. *Endocr Relat Cancer*. 2014 May 6;21(3):427-34. doi: 10.1530/ERC-14-0016. PMID: 24803525; PMCID: PMC4045219.

131: Welander J, Andreasson A, **Juhlin CC**, Wiseman RW, Bäckdahl M, Höög A, Larsson C, Gimm O, Söderkvist P. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab*. 2014 Jul;99(7):E1352-60. doi: 10.1210/jc.2013-4375. Epub 2014 Apr 2. PMID: 24694336; PMCID: PMC5393486.

132: Andreasson A, Kiss NB, **Juhlin CC**, Höög A. Long-term storage of endocrine tissues at - 80°C does not adversely affect RNA quality or overall histomorphology. *Biopreserv Biobank*. 2013 Dec;11(6):366-70. doi: 10.1089/bio.2013.0038. PMID: 24475321; PMCID: PMC3901954.

133: Andreasson A, Kiss NB, Caramuta S, Sulaiman L, Svahn F, Bäckdahl M, Höög A, **Juhlin CC**, Larsson C. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas. *Epigenetics*. 2013 Dec;8(12):1347-54. doi: 10.4161/epi.26686. Epub 2013 Oct 22. PMID: 24149047; PMCID: PMC3933494.

Christofer Juhlin, 791009-5632

134: Sulaiman L, **Juhlin CC**, Nilsson IL, Fotouhi O, Larsson C, Hashemi J. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism.

Epigenetics. 2013 Jun;8(6):646-55. doi: 10.4161/epi.24823. Epub 2013 Jun 13.

PMID: 23764768; PMCID: PMC3857344.

135: Kiss NB, Muth A, Andreasson A, **Juhlin CC**, Geli J, Bäckdahl M, Höög A,

Wängberg B, Nilsson O, Ahlman H, Larsson C. Acquired hypermethylation of the

P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor

phenotype and predisposing mutation. Endocr Relat Cancer. 2013 Feb

18;20(1):65-78. doi: 10.1530/ERC-12-0267. PMID: 23154831; PMCID: PMC3573842.

136: Sulaiman L, Haglund F, Hashemi J, Obara T, Nordenström J, Larsson C, Juhlin

CC. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated

parathyroid tumors. PLoS One. 2012;7(9):e46325. doi:

10.1371/journal.pone.0046325. Epub 2012 Sep 28. PMID: 23029479; PMCID:

PMC3460869.

137: Haglund F, Ma R, Huss M, Sulaiman L, Lu M, Nilsson IL, Höög A, **Juhlin CC**,

Hartman J, Larsson C. Evidence of a functional estrogen receptor in parathyroid

adenomas. J Clin Endocrinol Metab. 2012 Dec;97(12):4631-9. doi:

10.1210/jc.2012-2484. Epub 2012 Sep 28. PMID: 23024189.

138: Haglund F, Lu M, Vukojević V, Nilsson IL, Andreasson A, Džabić M, Bränström

R, Höög A, **Juhlin CC**, Larsson C. Prolactin receptor in primary

hyperparathyroidism--expression, functionality and clinical correlations. PLoS

Christofer Juhlin, 791009-5632

One. 2012;7(5):e36448. doi: 10.1371/journal.pone.0036448. Epub 2012 May 11.

PMID: 22606260; PMCID: PMC3350524.

139: Sulaiman L, Nilsson IL, **Juhlin CC**, Haglund F, Höög A, Larsson C, Hashemi J.

Genetic characterization of large parathyroid adenomas. *Endocr Relat Cancer*.

2012 May 24;19(3):389-407. doi: 10.1530/ERC-11-0140. PMID: 22454399; PMCID:

PMC3359501.

140: Andreasson A, Sulaiman L, do Vale S, Martins JM, Ferreira F, Miltenberger-

Miltenyi G, Batista L, Haglund F, Björck E, Nilsson IL, Höög A, Larsson C,

Juhlin CC. Molecular characterization of parathyroid tumors from two patients

with hereditary colorectal cancer syndromes. *Fam Cancer*. 2012 Sep;11(3):355-62.

doi: 10.1007/s10689-012-9520-z. PMID: 22395475.

141: Kauffmann RM, **Juhlin CC**, Fohn LE, Broome JT, Phay JE. Parathyroid carcinoma

arising from four-gland hyperplasia. *Endocr Pract*. 2011 Mar-Apr;17(2):e37-42.

doi: 10.4158/EP10211.CR. PMID: 21247853; PMCID: PMC3076624.

142: **Juhlin CC**, Haglund F, Obara T, Arnold A, Larsson C, Höög A. Absence of

nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant

tumours. *Virchows Arch*. 2011 Jul;459(1):47-53. doi: 10.1007/s00428-010-1032-3.

Epub 2011 Jan 8. PMID: 21221636.

143: **Juhlin CC**, Höög A. Parafibromin as a diagnostic instrument for parathyroid

carcinoma-lone ranger or part of the posse? *Int J Endocrinol*. 2010;2010:324964.

Christofer Juhlin, 791009-5632

doi: 10.1155/2010/324964. Epub 2010 Dec 12. PMID: 21197463; PMCID: PMC3005812.

144: Sofiadis A, Dinets A, Orre LM, Branca RM, **Juhlin CC**, Foukakis T, Wallin G, Höög A, Hulchiy M, Zedenius J, Larsson C, Lehtiö J. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca²⁺-binding protein S100A6 in papillary thyroid carcinoma. *Thyroid*. 2010 Oct;20(10):1067-76. doi: 10.1089/thy.2009.0400. PMID: 20629554.

145: Haglund F, Andreasson A, Nilsson IL, Höög A, Larsson C, **Juhlin CC**. Lack of S37A CTNNB1/ β -catenin mutations in a Swedish cohort of 98 parathyroid adenomas. *Clin Endocrinol (Oxf)*. 2010 Oct;73(4):552-3. doi: 10.1111/j.1365-2265.2010.03830.x. PMID: 20550535.

146: **Juhlin CC**, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. *Endocr Pathol*. 2010 Sep;21(3):166-77. doi: 10.1007/s12022-010-9121-z. PMID: 20473645.

147: Laurell C, Velázquez-Fernández D, Lindsten K, **Juhlin C**, Enberg U, Geli J, Höög A, Kjellman M, Lundeberg J, Hamberger B, Larsson C, Nilsson P, Bäckdahl M. Transcriptional profiling enables molecular classification of adrenocortical tumours. *Eur J Endocrinol*. 2009 Jul;161(1):141-52. doi: 10.1530/EJE-09-0068. Epub 2009 May 1. PMID: 19411298

148: **Juhlin CC**, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C. Frequent promoter hypermethylation of the APC and RASSF1A tumour

Christofer Juhlin, 791009-5632

suppressors in parathyroid tumours. PLoS One. 2010 Mar 1;5(3):e9472. doi:

10.1371/journal.pone.0009472. PMID: 20208994; PMCID: PMC2830427.

149: **Juhlin CC**, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, Larsson C, Höög A. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol. 2009 Feb;34(2):481-92. PMID: 19148484.

150: Lu M, Forsberg L, Höög A, **Juhlin CC**, Vukojević V, Larsson C, Conigrave AD, Delbridge LW, Gill A, Bark C, Farnebo LO, Bränström R. Heterogeneous expression of SNARE proteins SNAP-23, SNAP-25, Syntaxin1 and VAMP in human parathyroid tissue. Mol Cell Endocrinol. 2008 Jun 11;287(1-2):72-80. doi: 10.1016/j.mce.2008.01.028. Epub 2008 Mar 10. PMID: 18457912.

151: Geli J, Kogner P, Lanner F, Natalishvili N, **Juhlin C**, Kiss N, Clark GJ, Ekström TJ, Farnebo F, Larsson C. Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer. 2008 Jul 15;123(2):389-394. doi: 10.1002/ijc.23533. PMID: 18452173

152: **Juhlin CC**, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, Bränström R, Obara T, Arnold A, Larsson C, Höög A. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer. 2007 Jun;14(2):501-12. doi: 10.1677/ERC-07-0021. PMID: 17639063.

Christofer Juhlin, 791009-5632

153: Correa P, **Juhlin C**, Rastad J, Akerström G, Westin G, Carling T. Allelic loss in clinically and screening-detected primary hyperparathyroidism. *Clin Endocrinol (Oxf)*. 2002

Jan;56(1):113-7. doi: 10.1046/j.0300-0664.2001.01436.x. PMID: 11849254.

Not yet indexed in PubMed (n=3):

154: Lymphocytic adrenal medullitis: case report of a patient with pheochromocytoma-like hypertensive paroxysms. Calissendorff J, **Juhlin CC**. *ECED Reports*. October 2017. Not yet indexed in PubMed.

155: A Rare Case of Giant Amyloid Goiter: A Case Report and Review of Literature. **Juhlin CC**, Karlsson F, Bränström R. *Medical Case Rep*. May 2019. Not yet indexed in PubMed.

156: Adrenal cortical adenoma arising in an adreno-hepatic fusion: case report and literature review of a potential diagnostic pitfall. Adam Stenman, Ivan Shabo, Jan Zedenius and **C. Christofer Juhlin**. *Hum Pathol Case Rep* 2022. Not yet indexed in PubMed.